Waystar Weighs Sale Amid Falling Market Value, Sources Reveal

Waystar, a prominent healthcare software company known for its payment management solutions, is evaluating strategic alternatives, including a potential sale, according to seven insiders familiar with the situation. This move comes two years after the company's stock market debut in New York.

Based in Lehi, Utah, and Louisville, Kentucky, Waystar has engaged investment bank Evercore to guide the process. Two anonymous sources indicated that discussions are in the early stages, and no definitive outcome has been reached. The company and Evercore have declined to comment on these developments.

Market Challenges and Valuation Concerns

Waystar's market capitalization has declined to approximately $4.8 billion, reflecting a 24% decrease in share price this year amidst a broader downturn in the software sector. The exploration of a sale could test investor interest in software firms as the sector grapples with challenges such as advancing artificial intelligence technologies.

Initially, Waystar positioned itself as a technology entity focused on automating healthcare administrative tasks to attract the higher valuations typical of tech companies. This strategy initially paid off, with shares climbing from $20 to a peak of $45 in 2025. However, investor sentiment shifted due to concerns about potential disruptions from AI advancements, according to a July report by Morgan Stanley analysts.

Company Background and Ownership

Waystar emerged from the 2017 merger of Zirmed and Navicure, both leaders in healthcare revenue management. The firm's largest stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. These entities took Waystar public in 2024, with EQT holding a 13% share, CPPIB 10%, and BlackRock Institutional Trust Company 8%, as per LSEG data.

EQT and BlackRock have not provided comments on the potential sale, while CPPIB did not immediately respond to inquiries. Waystar's decision to consider a sale highlights the volatility and competitive pressures present in the healthcare software industry as companies navigate evolving market dynamics and technological advancements.